Efebera Yvonne A, Thandi Rupinderjit S, Saliba Rima M, Popat Uday, De Lima Marcos, Alousi Amin, Hosing Chitra, Rondon Gabriela, Champlin Richard, Giralt Sergio
Department of Stem Cell Transplantation and Cellular Therapies, University of Texas M.D. Anderson Cancer Center, Houston, TX.
Internet J Hematol. 2009;7(1).
Iron overload has been associated with increased non-relapse mortality (NRM) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing hematopoietic stem cell transplantation (HSCT). Elevated ferritin level pre-HSCT has been used as a marker for iron overload. It is unclear whether the negative effect of iron overload as measured by elevated ferritin level extends beyond the first three months post HSCT, as this would suggest a potential role for active management of iron overload post HSCT.
Sixty-three patients with AML and MDS who underwent an allogeneic HSCT from a sibling or unrelated donor between January to December 2006, had a pre-HSCT ferritin level and were alive and disease free 90 days post HSCT.
Median age was 51. Patients with the lowest pre-HSCT ferritin level (Q1) had a trend towards improved overall survival and progression free survival when compared to patients with higher level (Q2-Q4) (P=0.06, and 0.125). Cumulative incidence of NRM at 2 years was 20 and 30% respectively (P=0.4).
Pre-HSCT ferritin level may still have an impact on HSCT events beyond 3 months post transplant, suggesting a role for research into active management of iron overload with either phlebotomy or chelation.
铁过载与接受造血干细胞移植(HSCT)的急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者非复发死亡率(NRM)增加有关。HSCT前铁蛋白水平升高已被用作铁过载的标志物。目前尚不清楚,以铁蛋白水平升高衡量的铁过载的负面影响是否会在HSCT后三个月以上持续存在,因为这可能提示HSCT后积极管理铁过载具有潜在作用。
63例AML和MDS患者于2006年1月至12月间接受了来自同胞或无关供体的异基因HSCT,HSCT前有铁蛋白水平记录,且HSCT后90天存活且无疾病。
中位年龄为51岁。与铁蛋白水平较高(Q2-Q4)的患者相比,HSCT前铁蛋白水平最低(Q1)的患者总生存期和无进展生存期有改善趋势(P = 0.06和0.125)。2年时NRM的累积发生率分别为20%和30%(P = 0.4)。
HSCT前铁蛋白水平可能在移植后3个月以上仍对HSCT相关事件有影响,提示对采用放血或螯合疗法积极管理铁过载进行研究具有一定作用。